WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Insilico Medicine | March 25, 2022
A clinical-stage end-to-end artificial intelligence driven drug discovery firm, Insilico Medicine announced the formation of a strategic partnership with EQRx, a company dedicated to creating and delivering novel medications to patients at much-reduced costs.
The cooperation will use Insilico's Pharma.AI technology to accelerate the design and creation of de novo small molecules and EQRx's clinical development and commercialization experience. In addition, EQRx and Insilic...
Glenmark Pharmaceuticals Inc | October 19, 2020
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...
Ablexis, LLC, | January 31, 2022
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services, LLC (“ADS”), a leader in the discovery of superior antibody-based therapeutics, today announced a multi-target licensing agreement between Ablexis and Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall.
Under the terms of the license wi...
Sebela Pharmaceuticals | January 06, 2021
Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States.
SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE